-
1.发明申请Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders 失效用于治疗眼睛和CNS疾病的5-羟色胺能5HT7受体化合物公开(公告)号：US20050187214A1
公开(公告)日：2005-08-25
申请号：US11100918
申请日：2005-04-07
申请人： Jesse May , Thomas Dean , Najam Sharif , Hwang-Hsing Chen
发明人： Jesse May , Thomas Dean , Najam Sharif , Hwang-Hsing Chen
IPC分类号： C07D209/08 , C07D295/088 , C07D295/13 , C07D513/04 , C07D279/16 , A61K31/5415
CPC分类号： C07D295/088 , C07D209/08 , C07D217/04 , C07D235/26 , C07D295/13 , C07D401/12 , C07D513/04
摘要： Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.
摘要翻译： 公开了可用于降低IOP，改善视神经头和视网膜的血流量，提供神经保护和治疗视网膜疾病的具有5HT 7受体亲和力（其中一些是新颖的）的化合物。 化合物还可用于治疗睡眠障碍，抑郁症和其他精神病学障碍，例如精神分裂症，焦虑症，强迫症，昼夜节律紊乱以及中枢和外周介导的高血压。 还公开了其使用的组合物和方法。
-
2.发明申请Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders 有权用于治疗眼睛和CNS疾病的5-羟色胺能5HT7受体化合物公开(公告)号：US20060052372A1
公开(公告)日：2006-03-09
申请号：US11265030
申请日：2005-11-02
申请人： Jesse May , Thomas Dean , Najam Sharif , Hwang-Hsing Chen
发明人： Jesse May , Thomas Dean , Najam Sharif , Hwang-Hsing Chen
IPC分类号： A61K31/5415 , A61K31/18 , C07C279/02 , C07D417/02
CPC分类号： C07D295/088 , C07D209/08 , C07D217/04 , C07D235/26 , C07D295/13 , C07D401/12 , C07D513/04
摘要： Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.
摘要翻译： 公开了可用于降低IOP，改善视神经头和视网膜的血流量，提供神经保护和治疗视网膜疾病的具有5HT 7受体亲和力（其中一些是新颖的）的化合物。 化合物还可用于治疗睡眠障碍，抑郁症和其他精神病学障碍，例如精神分裂症，焦虑症，强迫症，昼夜节律紊乱以及中枢和外周介导的高血压。 还公开了其使用的组合物和方法。
-
3.发明申请(INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)-PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS 失效（INDAZOL-5-YL）-PYRAZINES和（1,3-二氢吲哚-2-酮） - 用于治疗RHO激酶介导的疾病和病症的药物公开(公告)号：US20070149548A1
公开(公告)日：2007-06-28
申请号：US11612894
申请日：2006-12-19
申请人： Mark Hellberg , Najam Sharif , Jesse May , Andrew Rusinko , Hwang-Hsing Chen
发明人： Mark Hellberg , Najam Sharif , Jesse May , Andrew Rusinko , Hwang-Hsing Chen
IPC分类号： A61K31/497 , A61K31/4965 , A61K31/557
CPC分类号： C07D403/14 , A61K9/0048 , A61K31/4965 , A61K31/497 , A61K31/557 , C07D403/04
摘要： Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.
摘要翻译： 本文公开了使用（吲唑-5-基） - 吡嗪和（1,3-二氢 - 吲哚-2-酮） - 吡嗪的方法来治疗rho激酶介导的疾病或rho激酶介导的病症，包括控制眼内压和 治疗青光眼。 用于治疗眼睛疾病如青光眼的眼用药物组合物，另外可用于控制眼内压，所述组合物包含有效量的（吲唑-5-基） - 吡嗪和（1,3-二氢 - 吲哚-2-基） 一种） - 吡嗪，这里公开。
-
4.发明申请HIGH THROUGHPUT ASSAY FOR HUMAN RHO KINASE ACTIVITY WITH ENHANCED SIGNAL-TO-NOISE RATIO 审中-公开具有增强信号噪声比的人类RHO激酶活性的高通量测定公开(公告)号：US20080096238A1
公开(公告)日：2008-04-24
申请号：US11951992
申请日：2007-12-06
申请人： Najam Sharif , Colene Drace , Gary Williams
发明人： Najam Sharif , Colene Drace , Gary Williams
IPC分类号： C12Q1/48
CPC分类号： C12Q1/485 , G01N2500/00
摘要： The present invention provides a high throughput assay with increased signal-to-noise ration for human Rho kinase activity in vitro, and methods and kits therefor. A high throughput method of assaying a test compound for human Rho kinase modulating activity is also provided.
摘要翻译： 本发明提供了一种高通量测定，其具有针对体外人Rho激酶活性的增加的信噪比，以及用于其的Rho激酶活性的方法和试剂盒。 还提供了测定化合物用于人Rho激酶调节活性的高通量方法。
-
5.发明申请Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance 审中-公开使用防止淀粉样蛋白和淀粉样蛋白样脂蛋白的产生的药剂，和/或促进这些蛋白质的螯合和/或降解和/或降解和/或预防神经毒性的药物用于治疗听力损失和改善身体平衡公开(公告)号：US20050137122A1
公开(公告)日：2005-06-23
申请号：US11005923
申请日：2004-12-07
申请人： Najam Sharif
发明人： Najam Sharif
IPC分类号： A61K31/20 , A61K31/353 , A61K31/553 , A61K31/7076 , A61K38/17
CPC分类号： A61K31/7076 , A61K31/20 , A61K31/353 , A61K31/553 , A61K38/046
摘要： The present invention provides compositions and methods for treating otic disorders. More specifically, the present invention describes the use of agents that down-regulate expression of Tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the ear.
摘要翻译： 本发明提供了治疗耳部疾病的组合物和方法。 更具体地，本发明描述了下调Tanis和/或p21Waf1 / Cip1 / Sd1基因表达以治疗这种耳朵病症的药剂的用途。
-
6.发明授权Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases 失效使用NR2B选择性NMDA受体拮抗剂治疗眼科疾病公开(公告)号：US06291479B1
公开(公告)日：2001-09-18
申请号：US09452004
申请日：1999-11-30
申请人： Najam Sharif
发明人： Najam Sharif
IPC分类号： A67K31445
CPC分类号： A61K31/4418 , A61K9/0048 , A61K31/445 , Y10S514/912
摘要： The invention is directed to the use of improved NR2B antagonists for the prevention and treatment of retinal or optic nerve head damage in mammals. Compositions and methods are disclosed.
摘要翻译： 本发明涉及改进的NR2B拮抗剂用于预防和治疗哺乳动物视网膜或视神经损伤的用途。 公开了组合物和方法。
-
7.发明申请USE OF NATRIURETIC PEPTIDE RECEPTOR ANTAGONISTS TO TREAT OCULAR, OTIC AND NASAL EDEMETOUS CONDITIONS 审中-公开使用胃肠肽受体拮抗剂治疗眼科，眼科和鼻咽麻醉病症公开(公告)号：US20070225225A1
公开(公告)日：2007-09-27
申请号：US11679991
申请日：2007-02-28
申请人： Najam Sharif , Parvaneh Katoli
发明人： Najam Sharif , Parvaneh Katoli
IPC分类号： A61K38/17 , A61K31/404
CPC分类号： A61K31/404
摘要： Methods and compositions to treat edematous ocular, otic and nasal conditions are described.
摘要翻译： 描述了治疗水肿性眼，耳和鼻状况的方法和组合物。
-
8.发明申请Use of agents that down-regulate expression of tanis and/or p21^Waf1/Cip1/Sd1 genes, and use of agents that inhibit, degrade, sequester or prevent the neurotoxicity of gene product proteins of tanis and p21^Waf1/Cip1/Sd1 genes 有权使用下调tanII和/或p21 ^ Waf1 / Cip1 / Sd1基因表达的试剂，以及使用抑制，降解，螯合或预防tanis和p21 ^ Waf1 / Cip1 / Sd1基因产物蛋白的神经毒性的试剂 基因公开(公告)号：US20050137123A1
公开(公告)日：2005-06-23
申请号：US11006007
申请日：2004-12-07
申请人： Colene Drace , Gary Williams , Curtis Kelly , Najam Sharif
发明人： Colene Drace , Gary Williams , Curtis Kelly , Najam Sharif
IPC分类号： A61K31/19 , A61K31/20 , A61K31/385 , A61K31/7072 , A61K38/04 , A61K38/17
CPC分类号： A61K31/385 , A61K31/19 , A61K31/20 , A61K31/7072 , A61K38/046
摘要： The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the eye.
摘要翻译： 本发明提供治疗青光眼，高眼压症和年龄相关性黄斑变性的组合物和方法。 更具体地说，本发明描述了使得下调和/或p21Waf1 / Cip1 / Sd1基因的表达下调的药物用于治疗这种眼睛疾病。
-
9.发明申请Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration 审中-公开使用阻止淀粉样样蛋白和/或玻璃疣生成的药剂，和/或使用促进螯合和/或降解和/或预防这些蛋白质治疗黄斑变性的神经毒性作用的药剂公开(公告)号：US20060121039A1
公开(公告)日：2006-06-08
申请号：US11006161
申请日：2004-12-07
申请人： Najam Sharif
发明人： Najam Sharif
IPC分类号： A61K48/00 , A61K39/395 , A61K38/17 , A61K31/737 , A61K31/401 , A61K31/366 , A61K31/137 , A61K31/655
CPC分类号： A61K38/046 , A61K9/0048 , A61K31/137 , A61K31/366 , A61K31/401 , A61K31/655 , A61K31/737
摘要： The present invention provides compositions and methods for treating age-related macular degeneration (AMD). More specifically, the methods of the invention target amyloid proteins and drusen that tend to accumulate in the eyes of those patients suffering from AMD. AMD is treated in the methods of the invention by providing agents that sequester and/or degrade such amyloid deposits and/or drusen such that a patient's vision is improved or restored.
摘要翻译： 本发明提供治疗年龄相关性黄斑变性（AMD）的组合物和方法。 更具体地，本发明的方法靶向倾向于在患有AMD的患者的眼睛中积累的淀粉样蛋白和玻璃疣。 通过提供螯合和/或降解这种淀粉样蛋白沉积物和/或玻璃疣的药剂来治疗本发明的方法，使得改善或恢复患者的视力。
-
公开(公告)号：US20060115870A1
公开(公告)日：2006-06-01
申请号：US11090689
申请日：2005-03-25
申请人： Najam Sharif , Colene Drace , Gary Williams
发明人： Najam Sharif , Colene Drace , Gary Williams
IPC分类号： C12Q1/48
CPC分类号： C12Q1/485 , G01N2500/00
摘要： The present invention provides a high throughput assay for human Rho kinase activity in vitro, and methods and kits therefor. A high throughput method of assaying a test compound for human Rho kinase modulating activity is also provided.
摘要翻译： 本发明提供了用于体外人Rho激酶活性的高通量测定，以及用于其的方法和试剂盒。 还提供了测定化合物用于人Rho激酶调节活性的高通量方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.02 秒)
